Ch
Chinook (Novartis)
Seattle WAFounded 2019200 employees
Private CapbiotechAcquiredNephrology
Platform: IgAN Compl
Market Cap
N/A
All Drugs
3
Clinical Trials
4
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Surazumab | CHI-9906 | Phase 2/3 | 1 | IL-17A | PBCHS | ||
| Capivorutinib | CHI-3822 | Phase 2 | 2 | IL-17A | MSADHD | ||
| CHI-3786 | CHI-3786 | Phase 2 | 1 | SOS1 | LNDravet |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (3)